STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents

AIDS activists criticized the Biden administration's R&D agreement with Gilead Sciences over HIV prevention drug patents, arguing it missed an opportunity to expand access to such tools. The deal resolved a Trump-era lawsuit alleging Gilead infringed CDC-funded research used to develop Truvada and Descovy, with the administration accusing Gilead of ignoring CDC contributions and refusing licensing agreements.